[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339104-105":59,"doc-detail-339104-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","is-oncotype-dx-testing-informative-for-breast-cancers-with-low-er-expression-a-retrospective-review","Is Oncotype DX testing informative for breast cancers with low ER expression? - A retrospective review","","Purpose: Determine whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer benefit from Oncotype DX (ODX) testing. Methods: Retrospective review of ODX referral cases over seven years (n=854), recording ODX Recurrence Score (RS) and ER nuclear positivity percentage plus staining intensity by immunohistochemistry, with ER-low defined as ≤10% nuclear positivity and/or weak staining. Results: 27 ER-low cases (3.2%); 92.6% had high RS (>25). Conclusion: ODX adds limited additional information for most ER-low patients; adding weak ER intensity increases ER-low identification but reduces specificity for high RS.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/is-oncotype-dx-testing-informative-for-breast-cancers-with-low-er-expression-a-retrospective-review/339104/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/is-oncotype-dx-testing-informative-for-breast-cancers-with-low-er-expression-a-retrospective-review/339104.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does the study address about ER-low breast cancer?","Question",{"text":112,"@type":113},"It evaluates whether HER2-negative ER-low-positive early breast cancer patients benefit from Oncotype DX testing when ER expression is low.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ER-low and ER-high groups defined in the study?",{"text":117,"@type":113},"ER-low was defined as ≤10% cells with nuclear positivity and/or weak staining intensity on immunohistochemistry; the comparator group used ER >10% positivity with non-weak staining (ER-high).",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about ODX Recurrence Scores in ER-low cases?",{"text":121,"@type":113},"Most ER-low cases (85.2%) had quantitative ER gene scores in the negative range, while 100% of ER-high cases had positive ER gene scores; 92.6% of ER-low cases had a high RS (>25).",{"name":123,"@type":110,"acceptedAnswer":124},"What conclusion did the authors draw about using ODX for ER-low breast cancer treatment decisions?",{"text":125,"@type":113},"ODX does not appear to provide significant additional information for most ER-low patients, though including weak ER staining intensity increases the number classified as ER-low with lower specificity for high RS.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},339104,1790699367,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","The Breast 75 (2024) 103715  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center John Loggie a, Penelope J. Barnes a, Michael D. Carter a, Daniel Rayson b, Gillian C. Bethunea, *\u003Cbr>a Department of Pathology and Laboratory Medicine, Dalhousie University, 5788 University Ave, Halifax, NS, B3H 1V8, Canada\u003Cbr>b Division of Medical Oncology, Department of Medicine, Dalhousie University, QEII-Bethune Building, 1276 South Park Street, Halifax, NS, B3H 2Y9, Canada |  |  | |\n| --- | --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>ER-low\u003Cbr>Breast cancer Estrogen receptor Oncotype DX Expression intensity Immunohistochemistry IHC |  | Purpose: It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing.\u003Cbr>Methods: We conducted a retrospective review of cases referred for ODX testing over a seven-year period from abreast biomarker testing referral center (n = 854). For each case, we recorded the ODX Recurrence Score (RS) along with percentage of ER nuclear positivity and staining intensity on immunohistochemistry. Our criteria for ER-low was defined as ≤10% cells with nuclear positivity and/or weak intensity of staining. Slides from all ERlow cases were reviewed and the reported ODX ER gene scores were recorded. We randomly selected a comparator group of 56 patients with ER > 10% positivity and non-weak staining intensity (ER-high).\u003Cbr>Results: We identified 27 cases (3.2%) that met our criteria for ER-low. Of these, 92.6% had a high RS (>25), and 7.4% had a RS of 25. All cases with ≤10% ER nuclear positivity had a high RS. Most ER-low cases (85.2%) had ODX quantitative ER gene scores in the negative range, whereas all (100%) ER-high cases had positive ER gene scores.\u003Cbr>Conclusion: ODX does not appear to add significant additional information to inform treatment decisions for most patients with ER-low BC. Incorporating weak ER staining intensity in addition to low percentage of nuclear positivity identifies about twice as many ER-low patients, although with reduced specificity for high RS. Our study supports the contention that most ER-low early BC should be regarded similarly to ER-negative BC. |  |\n\n1. Introduction  \nThe estrogen receptor (ER) is a critical predictive biomarker in breast cancer (BC). The majority of BCs are ER-positive, currently defined by the ASCO-CAP guidelines as tumors with ≥1% ER nuclear staining by IHC [1–3]. ER positivity is associated with more favorable clinical outcomes and is predictive of response to endocrine therapies (ETs). Early-stage BC generally refers to disease that can be treated with curative intent. Adjuvant systemic therapy for patients with early-stage ER-positive BC includes ET, with or without adjuvant chemotherapy (CT), whereas those with ER-negative BC are usually offered adjuvant or neoadjuvant chemotherapy alone. The therapeutic benefits of ER-targeted therapies have been shown to correlate with the level of ER expression in tumor cells [4] and there has been increasing interest in the characterization of BC with low levels of ER expression, herein referred to as ER-low. The definition of ER-low versus ER-high varies but is commonly based on the percentage of tumor cell nuclei with ER  \nexpression by IHC [5]. Historically, ER-low has been defined with cut-offs of up to ≤20% nuclear positivity [1,6–8], but there has recently been an emerging consensus definition of ≤10%[1,9,10]. The proportion of early-stage BC that meets this ER-low criteria ranged from 2 to 7% in a recent review [1].  \nOncotype DX (ODX) is a reverse transcriptase-polymerase chain rea","cbCaieoQJAhgyEsy","https://ap.wps.com/l/cbCaieoQJAhgyEsy","pdf",2394023,"English","# Purpose\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What clinical question does the study address about ER-low breast cancer?\",\"answer\":\"It evaluates whether HER2-negative ER-low-positive early breast cancer patients benefit from Oncotype DX testing when ER expression is low.\"},{\"question\":\"How were ER-low and ER-high groups defined in the study?\",\"answer\":\"ER-low was defined as ≤10% cells with nuclear positivity and/or weak staining intensity on immunohistochemistry; the comparator group used ER \\u003e10% positivity with non-weak staining (ER-high).\"},{\"question\":\"What did the results show about ODX Recurrence Scores in ER-low cases?\",\"answer\":\"Most ER-low cases (85.2%) had quantitative ER gene scores in the negative range, while 100% of ER-high cases had positive ER gene scores; 92.6% of ER-low cases had a high RS (\\u003e25).\"},{\"question\":\"What conclusion did the authors draw about using ODX for ER-low breast cancer treatment decisions?\",\"answer\":\"ODX does not appear to provide significant additional information for most ER-low patients, though including weak ER staining intensity increases the number classified as ER-low with lower specificity for high RS.\"}]","Is Oncotype DX testing informative for breast cancers with low ER expression? - A retrospective review | PDF",1790027905,13,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3fd20a425294f9ff0c2de948dce6fae.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d80bb5a1d5a2699b8a782d31e8ba007a.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38464c4ca97376b59bd799d66ad4e8e1.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/001eb6271d0d0e6ee7632a5c4fef3c41.webp",980,1306]